Home » UofL-born cell therapy startup completes $150 million IPO

UofL-born cell therapy startup completes $150 million IPO

By Baylee Pulliam
UofL News

A University of Louisville startup working to develop a therapy that could improve the lives of kidney transplant recipients and sufferers of severe autoimmune disease has completed a $150 million initial public offering. 

The company, Talaris Therapeutics Inc., has listed its shares on the NASDAQ Stock Market exchange under the ticker symbol “TALS.” 

Talaris is working to develop and market a novel allogeneic cell therapy, called FCR001, which is intended to help transplant recipients to stay off immunosuppression drugs they would otherwise need for the rest of their lives. The therapy was invented at UofL by researcher and innovator Suzanne Ildstad, who founded the company and now serves as its chief scientific officer.

The therapy is designed to prevent organ rejection without the morbidity and mortality that has been associated with the use of lifelong anti-rejection medicines. Talaris has an exclusive license to the technology, which was developed by Ildstad’s lab at UofL, through UofL’s Commercialization EPI-Center.

Immunosuppressants help prevent rejection of the transplanted organ, but can cause serious side effects, including high blood pressure, diabetes, high cholesterol, neurological effects, increased risk of infection and decline in kidney function over time.

With this therapy, the goal is “helping organ transplant recipients no longer be dependent on immunosuppressive drugs, resulting in a greatly improved quality of life,” Ildstad said previously. “The support and research infrastructure at UofL have been invaluable in our journey to this important juncture.”

Talaris has secured significant funding over the past two years. In 2019, the company closed a $100 million series A round, which it used to hire staff and initiate a Phase 3 clinical trial for its therapy — the last step before applying for FDA approval.

A year later, it secured $115 million in a series B funding round to support that trial as well as two other Phase 2 trials that are expected to begin in the second half of 2021, including a planned Phase 2 trial of FCR001 in diffuse cutaneous systemic sclerosis, a severe form of the rare autoimmune disease scleroderma.